Bracco Imaging announces completion of acquisition of Blue Earth Diagnostics
August 1, 2019
Oxford (UK), August 1st, 2019 – Bracco Imaging today announced that it has completed the acquisition of Blue Earth Diagnostics, a molecular imaging company based in Oxford, UK, from leading healthcare company Syncona Ltd. and Blue Earth Diagnostics’ management team.
Blue Earth Diagnostics is now officially a subsidiary of Bracco Imaging, led by its current leadership team and will retain the well-established Blue Earth Diagnostics name, and HQ in Oxford, UK, while maintaining a significant and operational presence across the US, based in Boston, Massachutes.
“We are thrilled to officially welcome to Bracco this world-class team with exceptional product development and commercialization expertise.” said Fulvio Renoldi Bracco, Chief Executive Officer, Bracco Imaging. “Our new relationship will enable both companies to realize their full potential by significantly broadening our combined portfolio in precision medicine and personalized diagnostics, while expanding our range of nuclear oncology imaging solutions in the Urology segment and other specialties.”
“Now begins the next stage in our adventure, as Blue Earth Diagnostics, a Bracco company,”, said Jonathan Allis, Chief Executive Officer at Blue Earth Diagnostics, “I am certain that it will be an exciting and meaningful one. We have the opportunity to work together with a world’s leading company in the diagnostic imaging business, to advance research and provide products that can make a meaningful difference in even more patients’ lives than ever before.”
Blue Earth Diagnostics employs approximately 100 people and is expected to generate revenues of $140M in the year to September 2019, primarily in the US.
Copy of the Bracco press release announcement acquisition and other corporate information can be found at: https://imaging.bracco.com/gb-en/bracco-imaging-expands-portfolio-personalized-diagnostics-acquisition-blue-earth-diagnostics